EVOLUTION AT MERCK - INVENTING FOR LIFE
GARDASIL: POSITIONED FOR RENEWED GROWTH
.
Growth driven by global appeals to
eliminate cervical cancer
Reacceleration of growth driven by
expansion into new geographies, public
and gender-neutral immunization programs
and age cohorts
•
Fastest pharmaceutical launch in China
Significant opportunity ahead given only
~3% of the world's eligible population has
received an HPV vaccine
Male
Female
Global incidence of HPV-related
cancers & diseases
Common
Oropharynx cancer
Recurrent Respiratory
Papillomatosis
MERCK
INVENTING FOR LIFE
11,000
Anal cancer
13,000 528,000
Cervical cancer
Penile cancer
18,200
17,300,000
Genital warts
14,400,000
Millions
of cases
Vulvar & vaginal
cancer
Cervical dysplasia
Current indications of GARDASIL 9
Not indicated
Frank Clyburn
25View entire presentation